Visceral leishmaniasis (kala-azar)-the Bihar (India) perspective

Journal of Infection

Volumn 53, Issue 1, 2006, Pages 60-64

  Sinha, P K ^a   Ranjan, A ^a   Singh, V P ^a   Das, V N R ^a   Pandey, K ^a   Kumar, N ^a   Verma, N ^a   Lal, C S ^a   Sur, D ^b   Manna, B ^b   Bhattacharya, S K ^a  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

Author keywords

Clinical features; Drug resistance; Epidemiology; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY GLUCONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; INDIA; INFECTION RISK; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANIMALS; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DEMOGRAPHY; DRUG RESISTANCE; FEMALE; HOSPITALS; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 33745510415     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2005.09.011     Document Type: Article

References (12)

1. World Health Organization. Life in the twenty-first century: a vision for all. World health report. Geneva: World Health Organization; 1998. p. 45.
2. World Bank. Investing in health. World development report (1993), Oxford University Press, New York
3. Desjeus P. Human leishmaniasis: epidemiology and public health aspects. World Health Stat Q 45 (1992) 267-275
4. Bora D. Epidemiology of visceral leishmaniasis in India. Nat Med J 12 2 (1999) 62-68
5. Sanyal R.K., Alam S.N., Kaul S.M., and Wattal B.L. Some observations on epidemiology of the current outbreak of kala-azar in Bihar. J Infect Dis 11 (1969) 170-176
6. Government of India. Economic attainment and well being. National human development report. Planning Commission, Government of India; 2001. p. 31-46.
7. Bhattacharya S.K., Jha T.K., Sundar S., Thakur C.P., Engel J., Sindermann H., et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 38 2 (2004) 217-221
8. Thakur C.P., Kumar M., and Pandey A.K. Comparison of regimen of treatment of antimony resistant kala-azar patients. Am J Trop Hyg 45 (1991) 435-441
9. Peter W. The treatment of kala-azar: the new approaches to an old problem. Indian J Med Res 73 (1981) 1-18
10. Sunder S. Treatment of visceral leishmaniasis-current status. J Assoc Physicians India 45 (1997) 640-645
11. Berman J.D. Chemotherapy of leishmaniasis biochemical mechanism, clinical efficacy and future strategies. Rev Infect 10 (1998) 560
12. Thakur C.P., and Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 98 2 (2004) 129-138